Why Beam Therapeutics Stock Tanked on Tuesday

Precision gene-editing company Beam Therapeutics (BEAM -19.68%) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced downwards to a more than 19% loss on the day. By comparison, the S&P 500 (^GSPC -0.77%) dipped by only 0.8% that trading session.The top line found wantingBeam, which is still in the clinical stage, earned slightly under $7.5 million in its first quarter of the year on license and collaboration revenue. That w ...